news careers Pipeline Our lead product candidate, batiraxcept (formerly AVB-500), is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials and has been granted Fast Track Designation by the U.S. Food and Drug Administration in platinum resistant recurrent ovarian cancer. The European Commission has granted orphan designation to batiraxcept for the treatment of platinum-resistant ovarian cancer. Analysis of all safety data to date showed that batiraxcept has been generally well tolerated with no dose-limiting toxicities or unexpected safety signals. A P1B platinum-resistant ovarian cancer trial (N = 53) demonstrated more than a doubling of progression-free survival in a patient subgroup that represents the P3 population. Platinum Resistant Ovarian Cancer Ovarian cancer ranks fifth in cancer deaths among women, and it is estimated that there will be approximately 21,410 new cases of ovarian cancer in the United States in 2021. Due to the nonspecific nature of disease symptoms and lack of validated screening tools in the general population, most women present with advanced disease. Although aggressive cytoreductive surgery and platinum- and taxane-based combination chemotherapy can place most patients into remission, disease recurrence manifests in greater than 70% of patients. Ultimately, patients who relapse become platinum-resistant and the identification of effective and tolerable treatment options is considered a high unmet clinical need. We are focused on addressing the high unmet need in this patient population and successfully completed a Phase 1b trial of batiraxcept in patients with platinum resistant ovarian cancer. We have initiated and are recruiting for a registrational Phase 3 trial of batiraxcept in platinum resistant ovarian cancer (NCT04729608). Clear Cell Renal Cell Carcinoma Kidney cancer is a leading cause of cancer-related deaths in the United States and is among the 10 most common cancers in both men and women. It is estimated that there will be approximately 76,080 new cases of kidney cancer and 13,780 people will die from this disease in the United States in 2021. Clear cell renal cell carcinoma is a cancer of the kidney and accounts for more than 75% of malignant kidney tumors. Metastasis to distant organs including the lung, bone, liver, and brain is the primary cause of death in kidney cancer patients, and only 12% of people with metastatic kidney cancer will survive past 5 years. We have initiated and are recruiting for a Phase 1b/2 clinical trial of batiraxcept in patients with clear cell renal cell carcinoma (NCT04300140). Pancreatic Adenocarcinoma Pancreatic cancer is the seventh leading cause of cancer death worldwide. There were approximately 495,800 new cases of pancreatic cancer and 466,000 deaths from the disease worldwide in 2020. It is estimated that there will be approximately 60,400 new cases of pancreatic cancer and 48,200 deaths from the disease in the U.S. in 2021. Pancreatic cancer typically has a poor prognosis, and the five-year survival rate is approximately 11%. Pancreatic adenocarcinoma is the most common type of pancreatic cancer, and there is a clear, high, unmet medical need to improve patient survival with new effective treatments that are safe and well-tolerated. Pancreatic cancer is projected to become the third leading cause of cancer death worldwide by 2025 and the second leading cause of cancer death in the U.S. by 2030. We have initiated and are recruiting for a Phase 1b/2 clinical trial of batiraxcept in patients with pancreatic adenocarcinoma (NCT04983407). ©2021 Aravive Terms of Use | Privacy Policy